Log In
BCIQ
Print this Print this
 

Biosimilar tocilizumab (BOW070)

  Manage Alerts
Collapse Summary General Information
Company Epirus Biopharmaceuticals Inc.
DescriptionBiosimilar of tocilizumab, a humanized mAb against IL-6 receptor
Molecular Target Interleukin-6 (IL-6) receptor (CD126)
Mechanism of ActionInterleukin-6 (IL-6) receptor (CD126) inhibitor; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Inflammation (unspecified)
Indication DetailsTreat inflammation
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$30.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/14/2015

$30.0M

0

0

Get a free BioCentury trial today